Ignite Creation Date:
2025-12-26 @ 11:11 PM
Ignite Modification Date:
2025-12-26 @ 11:11 PM
Study NCT ID:
NCT06010212
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-24
First Post:
2023-08-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2022-013-CH11 IIT-ESCC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None